Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie reports positive data from new rheumatoid arthritis drug trial

AbbVie reports positive data from new rheumatoid arthritis drug trial

21st December 2017

AbbVie has announced positive findings from a phase III clinical trial of a promising investigational therapy for rheumatoid arthritis drug.

Topline results from the SELECT-MONOTHERAPY study have highlighted the strong performance of upadacitinib, a new oral JAK1-selective inhibitor, as a monotherapy treatment in patients with moderate to severe rheumatoid arthritis who did not adequately respond to treatment with methotrexate.

After 14 weeks of treatment, once-daily upadacitinib treatment was able to deliver strong response rates and low disease activity, with both doses achieving all ranked and key secondary endpoints.

Further results from SELECT-MONOTHERAPY – which is the third of six studies in the SELECT rheumatoid arthritis clinical trial programme – will be presented at a future medical meeting and published in a peer-reviewed journal.

Dr Michael Severino, executive vice-president for research and development and chief scientific officer at AbbVie, said: "The positive results from the SELECT-MONOTHERAPY study are encouraging, as they are the first evidence to support the potential of upadacitinib as a therapy without the need for background methotrexate."

This drug is also being evaluated as a potential treatment for psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.